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Novelty statement: 
	This manuscript describes the first case of non-invasive prenatal diagnosis using cell free fetal DNA in a family with neonatal diabetes. 





An early genetic diagnosis of neonatal diabetes guides clinical management and results in improved treatment in approximately 40% of patients. In the offspring of individuals with neonatal diabetes, a prenatal diagnosis allows accurate estimation of risk of developing diabetes and, eventually, the most appropriate treatment for the baby. In this study we performed non-invasive prenatal genetic testing for a fetus at risk of inheriting a paternal KCNJ11 p.R201C mutation causing permanent neonatal diabetes.
Methods
A droplet digital PCR assay was used to detect the presence of the mutation in the cell free circulating DNA (cfDNA) extracted from maternal plasma at 12 and 16 weeks’ gestation.
Results
The mutation was not detected in the cfDNA samples, suggesting that the fetus had not inherited the KCNJ11 mutation. The fetal DNA fraction was estimated at 6.2% and 10.7%, which is above the detection limit of the assay. The result was confirmed by Sanger sequencing after the baby’s birth, confirming that the baby’s risk of developing neonatal diabetes was reduced to that of the general population.
Conclusions





Neonatal diabetes is diagnosed before 6 months of age and affects approximately 1:100,000 live births  ADDIN EN.CITE []. Almost 40% of patients people affected with neonatal diabetes have mutations in the genes encoding for the subunits of the ATP-sensitive potassium channel, ABCC8 and KCNJ11. Approximately 20% of individuals with a mutation in a KATP channel gene have additional neurological features, most commonly developmental delay and, in the more severe cases, early-onset epilepsy  ADDIN EN.CITE [, ]. A recent study suggested that all individuals with neonatal diabetes caused by mutations in ABCC8 or KCNJ11 have some degree of neurological impairment  ADDIN EN.CITE []. Most of these patients individuals can be successfully treated with sulphonylurea instead of insulin, leading to improved glycemic control and neurological function  ADDIN EN.CITE [, ]. Current evidence indicates that the earlier the sulphonylurea treatment is started the better is the outcome for the neurological function  ADDIN EN.CITE [, ]. An early genetic diagnosis of neonatal diabetes is therefore essential to guide treatment decision, with benefits for both diabetes and additional complications management  ADDIN EN.CITE [].
Analysis of the cell free fetal DNA (cffDNA) present in maternal blood provides a non-invasive means of testing pregnancies at high risk of genetic conditions. It has transformed prenatal genetic testing for Down syndrome  ADDIN EN.CITE []. CffDNA is present in the maternal circulation from the first trimester at a proportion of ~10% of the total circulating DNA []. The implementation of highly sensitive techniques such as massively parallel deep sequencing  ADDIN EN.CITE [] and droplet digital PCR  ADDIN EN.CITE [] allows the detection of variants that are present in the fetus but not in the maternal DNA (either paternally inherited or de novo) with high reliability. 
In this report we describe the use of a droplet digital PCR (ddPCR) assay for non-invasive prenatal testing in the fetus of a couple where the father has permanent neonatal diabetes due to a heterozygous KCNJ11 p.R201C mutation.

Patients and Methods
Informed consent was obtained from the couple. Cell free DNA (cfDNA) was extracted from maternal plasma collected at 12 and 16 weeks’ gestation using the Chemagic Circulating NA kit (Perkin Elmer). Detection of the KCNJ11 c.601C>T, p.R201C mutation (NM_000525.3) was carried out by ddPCR. A custom Life Technologies TaqMan assay was designed to detect the C (reference) and T (mutated) alleles: forward PCR primer, CGGCCGCCTCTGCTT; reverse PCR primer, TCATGCTCTTGCGGAGGTC; probe 1 (C allele), VIC-ACCCACACGTAGCATG-NFQ; 
probe 2 (T allele), FAM-CCCACACATAGCATG-NFQ. This assay was used in reactions for droplet generation, PCR and detection using the Bio-Rad QX200 ddPCR system as recommended by the manufacturers, with an annealing/extension temperature during PCR of 55C. All data was analysed using Bio-Rad QuantaSoft software, with merging of data for multiple wells where relevant.
Assays were performed on paternal genomic DNA (gDNA) (known genotype C/T), maternal gDNA (known genotype C/C) and cfDNA extracted from maternal plasma (genotype and gender unknown). To establish the sensitivity of the assay for the T allele in a background of maternal gDNA, control samples were prepared in which paternal gDNA was spiked into maternal gDNA at concentrations of 10%, 1% and 0.1% of total DNA. 
To establish the proportion of cell free fetal DNA (cffDNA) in the cfDNA samples from maternal plasma, parental genomic DNA samples were assayed by ddPCR using a panel of common SNPs to identify one for which the fetus would be an obligate heterozygote. The SNP selected was rs4536103 (NEUROG3, NM_020999.3:c.596T>C) at which mother and father were homozygous for the A or G alleles respectively. Thus the presence of the paternally inherited G allele in the cfDNA sample allowed accurate estimation of the percentage of cffDNA in the 12 and 16 week samples.

Results
Counts of the C (reference) and T (mutated) alleles for the KCNJ11 c.601C>T mutation in paternal and maternal gDNA using ddPCR were consistent with the known genotypes of these samples (father heterozygous C/T, mother homozygous C/C), with paternal alleles present at a 50:50 ratio (within 95% Poisson confidence intervals) as expected (Figure 1A). 
The sensitivity of the assay was assessed using maternal gDNA spiked with paternal gDNA at various concentrations. The fraction of fetal DNA in maternal cfDNA is typically in the range 2-20% [11], and we were able to readily detect the paternal T allele when spiked into maternal gDNA at 1% concentration (data not shown). We set a conservative limit for reliable detection of the T allele as 10 positive droplets across all wells analysed (26,881 droplets total for the 1% spiked sample), which equates to ~18 copies of amplifiable DNA. No droplets positive for the T allele were observed in negative (no template) controls or in maternal gDNA samples. Analysis of cfDNA extracted at either 12 or 16 weeks’ gestation showed that while the C allele was abundant, the T allele was not reliably detected. Pooled data from replicate wells gave an apparent concentration of 0.016 copies per μl in the 12-week sample (one positive droplet observed out of 74,635 analysed), while no positive droplets for the T allele were observed in the 16-week sample (Figure 1A). These results suggest that the fetus had not inherited the KCNJ11 p.R201C mutation. 
Estimation of the fetal DNA fraction in the two cfDNA samples using  rs4536103 (for which the fetus was an obligate heterozygote) confirmed the presence of cffDNA at a relative amount of 6.2% in the 12 weeks’ gestation sample and 10.7% in the 16 weeks’ sample, consistent with previous reports [] (Figure 1B). 
Given the fetal fractions measured using rs4536103, had the fetus inherited the paternal KCNJ11 c.601T allele this would have been expected at an abundance of ~173 copies or ~114 copies in the ddPCR assay. Since these values are well above the limit of sensitivity, this confirms that the absence of the mutant allele was due to non-inheritance and not due to a failure to detect the allele as a result of low fetal fraction. The risk of the baby developing neonatal diabetes was therefore reduced to that of the population, and non-inheritance of the KCNJ11 p.R201C mutation was confirmed by direct Sanger sequencing of a DNA sample extracted from cord blood soon after the baby’s birth.

Discussion
We describe the application of a droplet digital PCR assay for non-invasive prenatal genetic testing in the offspring of a father heterozygous for a KCNJ11 p.R201C mutation causing neonatal diabetes. Our assay showed that the fetus had not inherited the mutation and this result was confirmed after birth. This is the first report of prenatal diagnosis using cell free fetal DNA in a family with neonatal diabetes.
Early diagnosis of neonatal diabetes is essential to provide the most appropriate treatment, since most individuals with mutations in the potassium channel genes achieve improved glycemic control upon switching from insulin to sulphonylurea therapy  ADDIN EN.CITE [, ]. Furthermore, early treatment with high dose sulphonylureas is likely to improve neurological development in the 20% of patients individuals with neurological features. In the case we report, the fetus had not inherited the mutation and we could reassure the parents that his risk of developing neonatal diabetes was reduced to that of the population. This couple had sought prenatal testing in order to be prepared for the birth of a baby likely to develop diabetes during the first weeks of life. If the baby had inherited the mutation, his blood glucose would have been closely monitored and sulphonylurea therapy initiated promptly.
In this case the father was affected with neonatal diabetes so cffDNA analysis of the KCNJ11 mutation was focused on detection of an allele that was not present in the maternal circulating DNA. Detection of mutations that are maternally inherited is more challenging because of the background of maternal genome confounding the analysis. Improvement of cffDNA prenatal testing using highly sensitive techniques such as ddPCR may overcome this difficulty, allowing reliable testing for maternally inherited mutations. Prenatal testing is particularly relevant for optimal management of diabetes in pregnant women with a mutation in one of the genes (KCNJ11 or ABCC8) encoding the potassium channel subunits. Previous studies have shown that sulphonylureas can cross the placenta and influence fetal growth, potentially resulting in macrosomia and neonatal hyperinsulinemia in babies who do not inherit the mutation  ADDIN EN.CITE [].
Knowledge of the fetal genotype will influence both pre-natal and post-natal management of pregnancies where one parent is affected with neonatal diabetes. We illustrate how non-invasive prenatal testing using cffDNA allowed accurate and timely diagnosis for a pregnancy at risk of neonatal diabetes due to a paternal mutation. Although the clinical impact of this novel technology still needs to be formally assessed, we anticipate that its implementation in clinical practice (including cases at risk of inheriting maternal mutations) will likely provide clinical benefits for families affected by monogenic diabetes.
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1A Allele concentration for the KCNJ11 c.601C>T mutation. The graph shows data for DNA samples from father, mother, 12 weeks cfDNA and 16 weeks cfDNA, as labelled; grey bars represent the C allele, red bars represent the T allele (mutated). The y-axis shows allele concentration (copies/μl, as reported by QuantaSoft software) on a linear scale, with data labels showing allele concentrations for individual samples; error bars show 95% Poisson confidence limits, as calculated by QuantaSoft. Total numbers of droplets analysed were: paternal gDNA, 11,808; maternal gDNA, 12,798; 12 weeks cfDNA sample, 74,635; 16 weeks cfDNA sample, 48,168.
1B Estimation of fetal fraction from the allele concentration of SNP rs4536103. The same samples shown in figure 1A were assayed for SNP rs4536103 (blue bars represent A allele, green bars represent G allele). Allele concentration (copies/μl) is shown on the y-axis using a linear scale. Data labels above each bar show allele concentration in individual samples; error bars show 95% Poisson confidence limits. Total numbers of droplets analysed were:  paternal gDNA, 13,774; maternal gDNA, 12,371; 12 weeks cfDNA sample, 39,163; 16 weeks cfDNA sample, 54,576. Estimated fetal fraction in cfDNA (calculated as ((n copies of paternal allele * 2) / total n copies)%) is indicated under the graph. 


